STRATA Skin Sciences Announces New Recurring Revenue Direct Distribution Contract with JMEC Co., Ltd. in Japan
- Strengthens the STRATA XTRAC® and VTRAC® brand value proposition in
Japanto expand the installed base of over 300 devices in-country
- Takes advantage of STRATA’s strong balance sheet to support the unique recurring revenue business model, now in
- Leverages the over 15-year relationship with JMEC, a preeminent medical device distributor active in
Japansince 1995, distributing and providing support for STRATA Excimer devices since 2005
- The treatment by 308nm Excimer is covered by Japan’s national health insurance with reimbursement rates of
- Provides a strategy to target the over 12,000 dermatologists in
Japanwith an enhanced and unique business proposition never before seen in the Japanese clinical dermatology market
- STRATA expects to see the impact of the recurring revenue business model in
Japanas early as the end of 2020
“We are very pleased to continue to expand globally by bringing our unique business model to
The Japanese dermatology market comprises over 12,000 physicians. XTRAC and VTRAC have been sold and are used by over 300 hospitals and private practice clinics.
Japan’s vitiligo and psoriasis patient population is approximately 0.7 million. The treatment by 308nm Excimer is covered by the national health insurance with reimbursement rates of
The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases, which impact over 35 million patients in
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 789 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10-mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to generate the growth in its core business, develop and grow an international recurring business model, the Company’s ability to develop social media marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the corona virus and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company’s
Source: STRATA Skin Sciences, Inc.